Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation

Juan Chen, Hongtao Wang, Jiaxi Zhou and Sizhou Feng

Abstract: Poor graft function (PGF) following allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a life-threatening complication and is characterized by bilineage or trilineage blood cell deficiency and hypoplastic marrow with full chimerism. With the rapid development of allo-HSCT, especially haploidentical-HSCT, PGF has become a growing concern. The most common risk factors illustrated by recent studies include low dose of infused CD34+ cells, donor-specific antibody, cytomegalovirus infection, graft versus host disease (GVHD), iron overload and splenomegaly, among others. Because of the poor prognosis of PGF, it is crucial to uncover the underlying mechanism, which remains elusive. Recent studies have suggested that the bone marrow microenvironment may play an important role in the pathogenesis of PGF. Deficiency and dysfunction of endothelial cells and mesenchymal stem cells, elevated reactive oxygen species (ROS) levels, and immune abnormalities are believed to contribute to PGF. In this review, we also discuss recent clinical trials that evaluate the safety and efficacy of new strategies in patients with PGF. CD34+–selected stem-cell boost (SCB) is effective with an acceptable incidence of GVHD, despite the need for a second donation. Alternative strategies including the applications of mesenchymal stem cells, N-acetyl-l-cysteine (NAC), and eltrombopag have shown favorable outcomes, but further large-scale studies are needed due to the small sample sizes of the recent clinical trials.

Keywords: allogeneic hematopoietic stem-cell transplantation, mechanism, poor graft function, risk factors, treatment

Introduction

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is important and the only curative treatment for some malignant or nonmalignant hematopoietic diseases. Most patients can achieve hematopoietic recovery after allo-HSCT, but a portion of them develop graft failure (GF), which is caused primarily by graft rejection and poor graft function (PGF) that can be distinguished by the chimerism status. While full chimerism exists for PGF, mixed chimerism is present in graft rejection. This review will focus on PGF.

The criteria for PGF have not been agreed. However, most recent studies have defined PGF based on the severity of cytopenia of at least two cell types: (1) absolute neutrophil count (ANC) \( \leq 0.5 \times 10^9/l \); (2) platelet (PLT) count \( \leq 20 \times 10^9/l \); and (3) hemoglobin (HB) \( \leq 70 \, \text{g/l} \) for at least 3 consecutive days beyond day +28 post-HSCT or the requirement of transfusion support with hypoplastic-aplastic bone marrow, excluding severe graft versus host disease (GVHD) and relapse. Primary PGF refers to incomplete engraftment, while secondary PGF is defined as a loss of initial engraftment. Patients with primary PGF have a lower response rate to treatment and poorer prognosis compared with those with secondary PGF. PGF is a life-threatening complication, and the survival rate is significantly lower.
than patients with good graft function (GGF). This is because persistent leukocytopenia and thrombocytopenia increase the risk of infections and bleeding, and, thus, raise the mortality rate. The incidence of PGF is approximately 5–27%\textsuperscript{3,5} and has become a growing obstacle after allo-HSCT due to the development of haploidentical-HSCT. However, the underlying mechanism has yet to be elucidated, while treatments are very limited. Recent studies suggested that the bone marrow (BM) microenvironment plays an important role in the pathogenesis of PGF and may provide potential new targets for treatments. Also, the therapeutic strategies such as CD34\textsuperscript{+}-selected stem-cell boost (SCB), mesenchymal stem-cell (MSC) infusion and other new approaches have shown good efficacy and may provide potential new treatments for PGF.

### Risk factors

Risk factors for PGF include low dose of infused CD34\textsuperscript{+} cells, cytomegalovirus (CMV) infection, GVHD, donor-specific antibody (DSA), iron overload, splenomegaly and so on.\textsuperscript{2-3,6} In addition, CMV infection and GVHD are more likely associated with secondary PGF, rather than primary PGF.\textsuperscript{4}

In previous studies,\textsuperscript{7,8} the dose of CD34\textsuperscript{+} cells is crucial for hematopoietic and immune recovery after allo-HSCT. After comparing two recent studies, we conclude that a higher CD34\textsuperscript{+} cell dose (5.5×10\textsuperscript{5}/kg \textit{versus} 2.21×10\textsuperscript{5}/kg) is linked consistently with a lower risk of developing PGF (2.89% \textit{versus} 5.6%; \(p = 0.015\)).\textsuperscript{4,3} Zhao \textit{et al.} suggested that the CD34\textsuperscript{+} cell dose <5×10\textsuperscript{5}/kg [odds ratio (OR) = 5.089; 95% confidence interval (CI): 1.745–14.841, \(p = 0.003\)] might be an independent risk factor for primary PGF as revealed by multivariate logistic analysis.\textsuperscript{3} In addition, a retrospective study focused on secondary PGF also suggested that the low (<median) CD34\textsuperscript{+} cell dose is an independent risk factor [hazard ratio (HR) = 3.07; 95% CI: 1.207–7.813; \(p = 0.019\)].\textsuperscript{9}

DSA against the unshared haplotype in the recipient is reportedly associated with an increased risk of engraftment failure in unrelated donor transplantation and haploidentical-HSCT.\textsuperscript{10,11} Moreover, a recent study conducted by our colleagues suggested that DSA is the only risk factor for engraftment failure (OR=34.0; 95% CI: 2.648–436.545; \(p = 0.007\)).\textsuperscript{12} Sun \textit{et al.} found that DSA-positive patients are more inclined to develop primary PGF (31% \textit{versus} 3.2%, \(p = 0.000\)) than the DSA-negative patients.\textsuperscript{4} Moreover, a prospective study with a total of 345 cases showed that DSA (MFI >2000) is strongly associated with PGF.\textsuperscript{13} In 2018, the European Society for Blood and Marrow Transplantation recommended testing DSA in all haploidentical donor transplant recipients and suggested MFI >1000 as DSA positivity.\textsuperscript{14} In summary, the high DSA level is associated with the occurrence of PGF, and DSA-positive donors should be avoided. However, for patients with limited donor options, with careful DSA assessment and monitoring, the desensitization to weak or negative DSA levels may allow successful transplantation.\textsuperscript{15,16} Our previous study indicated that the combination of rituximab and donor platelet can reduce the DSA level and improve engraftment.\textsuperscript{12} Recently, Bramanti \textit{et al.} demonstrated that low-level DSA does not increase the risk of PGF development, even without desensitization, but the criteria that make haploidentical-HSCT permissible need to be further identified.\textsuperscript{17}

Iron is an essential element for hematopoiesis. However, iron overload can lead to the accumulation of reactive oxygen species (ROS) and exert a suppressive effect on the bone marrow microenvironment and differentiation of human CD34\textsuperscript{+} cells, thus disrupting hematopoiesis.\textsuperscript{18} Moreover, iron is also an important nutrient for bacteria and fungi, and, as such, iron overload makes patients more susceptible to infections.\textsuperscript{19} Serum ferritin (SF) is a form of iron storage and has been used widely as a biomarker of iron overload. A recent study, identified the SF level >2000 ng/ml as an independent risk factor for primary PGF (OR = 4.147; 95% CI: 1.452–11.845; \(p = 0.008\)), and the patients of SF level >2000 ng/ml had a poor 1-year overall survival.\textsuperscript{3} Splenomegaly is reportedly another risk factor of primary PGF,\textsuperscript{3,20,21} although the underlying diseases are heterogeneous. The possible mechanism might be that enlarged spleen could trap and destroy hematopoietic cells. Splenomegaly defined as splenic thickness >4 cm or craniocaudal length >12 cm is an independent risk factor for PGF (OR = 3.306; 95% CI:1.062 to 10.289; \(p = 0.039\)).\textsuperscript{3} Alchalby \textit{et al.} suggested that the
persistence of significant splenomegaly (≥10 cm under costal margin) at day +30 after HSCT exhibits a higher incidence of PGF (33% versus 12%; \( p = 0.05 \)) in patients with myelofibrosis.

Enlarged spleen (≥320 cm³) is linked to low neutrophil and platelet engraftment after allo-HSCT in patients of acute myeloid leukemia and myelodysplastic syndrome. Interestingly, Akpek et al. found that, when a CD34⁺ cell dose > 5.7 × 10⁶/kg is transplanted, delayed engraftment caused by splenomegaly can be counteracted, indicating that higher doses of CD34⁺ cells should be considered for patients with an enlarged spleen.

Cytomegalovirus infection is a common complication after allo-HSCT, and occurs in approximately 30–70% patients. CMV can inhibit hematopoiesis directly by infecting bone marrow or suppress hematopoiesis indirectly through the infection of stromal cells. Moreover, the treatment of CMV infection, especially with ganciclovir, exhibits bone marrow suppressive effects. Clinical data showed that patients with CMV infection after allo-HSCT are at a higher risk of PGF (OR = 9.146; 95% CI: 1.513–55.276; \( p = 0.016 \)). In secondary PGF, CMV reactivation is also an independent risk factor (HR = 7.827; 95% CI: 2.002–30.602; \( p = 0.003 \)). Human herpesvirus 6 (HHV-6) is closely related to human cytomegalovirus and can affect over 90% of healthy individuals during childhood. It is recognized in 30% to 60% allo-HSCT recipients, especially in those of unrelated cord blood graft. Moreover, HHV-6 infection is reportedly associated with delayed engraftment, especially in early reactivating patients.

GVHD is an immune-associated complication after allo-HSCT, and the bone marrow microenvironment is impaired in GVHD patients. A previous study showed that patients with GVHD (grades I–IV) have significantly lower platelet counts on day +50 post-HSCT. Peralvo et al. demonstrated that PGF is associated with acute GVHD (aGVHD) grade II or more and that aGVHD is the major risk factor (\( p = 0.001 \)) for the development of PGF. Moreover, in patients with PGF, hemopoietic recovery is strongly associated with the resolution of aGVHD. Other risk factors reported by previous studies include elder age, mismatch of donor-recipient blood type, advanced underlying diseases, the intensity of pre-conditioning regimen, HLA-disparity, etc.

The mechanism

Hematopoiesis is a dynamic process throughout the lifetime as blood cells are continually replenished. Self-renewal and directed differentiation are two cardinal properties of hematopoietic stem cells (HSCs). The BM microenvironment, also known as the HSC niche, can maintain and regulate HSC behavior, such as proliferation, maintenance, retention, and quiescence. The HSC niche was first proposed by Schofield in 1978, and has been widely studied since then, especially in the past decades. Earlier studies revealed a mostly endosteal location for HSCs, while osteoblastic cells are the first cell type shown to influence hematopoietic stem-cell frequency. However, more recently, accumulating studies demonstrated that the majority of HSCs located in the perivascular and highly vascular endosteal region. Because HSCs are located near blood vessels, it is critical to investigate the perivascular microenvironment (including stromal cells, cytokines, etc.). Perivascular stromal cells mainly include mesenchymal stem cells (MSCs), endothelial cells (ECs), adipolineage cells, megakaryocytes, macrophages, regulatory T cells (Tregs), and osteoblasts. Recent studies in the murine models indicated that mesenchymal stem cells, endothelial cells, Treg cells, macrophages, and the cytokines (SCF and CXCL12) secreted by these cells are key components of the niche in the regulation of HSCs. Moreover, evidence has been presented that HSCs reside within relatively hypoxic domains of bone marrow. Although the mechanism underlying PGF has not been elucidated, the BM microenvironment has been recently reported as crucial in the pathogenesis of PGF.

Endothelial cells

Endothelial cells are important stromal cells around the vasculature. Zeng et al. suggested that endothelial progenitor cells (EPCs) can accelerate the recovery of BM vasculature and cellularity and facilitate hematopoietic and immune reconstitution in murine models. Recently, Kong et al. performed two prospective studies and demonstrated that the number of BM ECs was significantly reduced in PGF patients both primarily and
secondarily. Moreover, low count of endothelial progenitor cells is an independent risk factor for secondary PGF (OR = 150.72; 95% CI: 7.85–2893; \(p = 0.001\)). In addition, BM ECs in subjects with PGF are not only deficient but also dysfunctional, with impaired proliferation, migration, and angiogenesis, and higher levels of ROS and apoptosis.\(^{53}\)

In summary, the impairment of BM ECs may contribute to the occurrence of PGF after allo-HSCT.

**Mesenchymal stem cells**

Mesenchymal stem cells are crucial components of the perivascular niche to support and regulate HSCs.\(^{35,37,44}\) An earlier case-control study by Song et al. showed that BM MSCs from PGF patients decrease in frequency and exhibit more apoptosis and senescence.\(^{54}\) In addition, intracellular ROS, p-p53, and p21 levels were elevated in MSCs from PGF patients. Furthermore, the impairment of MSCs results in the deficient ability to sustain hematopoiesis in PGF patients. Therefore, these data indicated that MSCs may be impaired in PGF patients after allo-HSCT and that improvement of BM MSCs may provide a promising therapeutic strategy.

**Elevated ROS levels**

The BM microenvironment or the HSC niche is normally hypoxic and maintains the essential HSC functions, such as cell cycle control, survival, and metabolism by protecting HSCs against oxidative stresses.\(^{42,55}\) A series of studies showed that, although similar numbers of donor CD34\(^+\) cells were transplanted, with the function of HSCs pre-HSCT being similar, the percentages of BM CD34\(^+\) cells in PGF patients were significantly lower compared with those in GGF patients after allo-HSCT.\(^{51,52,56}\) Furthermore, elevated ROS levels are reportedly associated with the exhaustion of quiescent CD34\(^+\) cells in subjects with PGF following allo-HSCT.\(^{56}\) These findings suggested that elevated ROS might cause exhaustion of quiescent BM CD34\(^+\) cells in PGF patients even if CD34\(^+\) cells from donors are functionally normal pre-HSCT.

**Immune abnormalities**

Increasing evidence showed that the BM immune microenvironment is vital for the regulation of hematopoiesis.\(^{57–59}\) A recent case-control study revealed a significant increase in M1 (classically activated inflammatory macrophages) and a striking reduction in M2 (alternatively activated anti-inflammatory macrophages) in PGF patients compared with those with GGF.\(^{60}\) The functions of BM macrophages, such as proliferation, migration, and phagocytosis, were impaired in PGF patients. Moreover, when cocultured with BM macrophages from PGF patients, the function of CD34\(^+\) cells was impaired through the upregulation of the p38 MAPK pathway. Two recent studies revealed that the dysregulated T cell responses may also contribute to the occurrence of PGF after HSCT.\(^{61,62}\) Compared with GGF patients and healthy donors, patients with PGF contain significantly higher proportions of Th1 and Tc1 cells (which produce IFN-\(\gamma\)) and reduced proportions of Th2 and Tc2 cells (which produce IL-4), leading to a shift of Th1/Th2 and Tc1/Tc2 ratios towards a type 1 response.\(^{61}\) Furthermore, Th17 and Tc17 cells, which produce IL-17, are significantly elevated in PGF patients. However, Tregs, which are considered as suppressor T cells and key players in regulating immune responses, are comparable in PGF and other subjects. Thus, the Th17/Treg ratio is elevated dramatically in PGF patients.\(^{62}\) Also, in patients with prolonged thrombocytopenia after allo-HSCT, the levels of inflammation-associated cytokines, including IGFBP1 (insulin-like growth factor–binding protein 1) and RANTES (regulated on activation, normal T cell expressed and secreted) were elevated, which impaired the megakaryocytic potential of HSCs.\(^{63}\) Recently, immune mechanisms have been suggested in some donor-type late graft failure with full chimerism (secondary PGF), including increased glycosylphosphatidyl inositol-anchored protein-deficient (GPI-AP\(^-\)) leukocytes and HLA-allele-lacking leukocytes. Furthermore, in patients with increased GPI-AP\(^-\) cells, hematopoiesis may be restored by anti-thymocyte globulin (ATG) therapy alone without further donor stem-cell infusion, indicating immunosuppressive therapy should be considered in these patients.\(^{64}\) Together, immune responses are more active in PGF patients, and the BM immune microenvironment might play an important role in PGF.

**Treatments**

Traditional treatments for PGF patients include mainly the administration of hematopoietic growth factors, donor cell infusion, and second
allo-HSCT, but efficacy is limited. Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) can improve the number of neutrophils and hemoglobin levels, but they are usually effective in the short term, and persistent treatment can lead to alloimmunization and transfusion-related iron overload. The second transplantation and donor cell infusion have shown efficacy. However, long-term survival has not been significantly improved due to the high morbidity of severe GVHD. To reduce the risk of acute and chronic GVHD, CD34+-selected stem-cell boost (SCB) has become an alternative treatment for patients with PGF. More recently, with an improved understanding of the mechanisms, MSCs infusion and other new strategies have emerged and demonstrated promising efficacy and good tolerance. Comparisons of recent clinical research in the treatment of PGF are shown in Table 1.

**CD34+-selected SCB**

Over the past decades, most studies of the treatment of PGF have been focused on the use of CD34+-selected stem-cell boost without pre-conditioning, leading to favorable outcomes. Stasia et al. reported that, after 41 PGF patients were treated with CD34+-selected SCB of different donor types, the overall response rate and tri-lineage recovery rate were 83% and 75%, respectively, with no significant disparity in different donor subgroups. More importantly, the procedure was safe, with a low risk of grade II acute GVHD (15%) and patients with previously chronic GVHD did not worsen after infusion. A small-scale study by Haen et al. included 20 adult patients with PGF after allo-HSCT, which were treated with selected CD34+ SCB by immunomagnetic beads from matched unrelated, mismatched unrelated, or haploidentical donors. They reached rapid engraftment in approximately 90% of all patients, after a median of 14, 13, and 18 days for platelets, leukocytes, and hemoglobin, respectively. In a long-term follow up, the improvement of hematopoiesis (92%) is more favorable compared with previous results. Moreover, the researchers did not observe any SCB-related toxicities and found only very limited complications (e.g. only one patient developed GVHD). These advantages may attribute to CD34+-selected SCB with as low T cell numbers as possible. Another study focused mainly on pediatric patients (n = 50) also identified good tolerance and efficacy. To generate SCB, donors traditionally must undergo an additional peripheral blood stem-cell (PBSC) collection. However, realistically, many patients might not be able to receive fresh SCB if their donors are unwilling or unable to accept another PBSC collection. Under these circumstances, cryopreserved cells from the donor’s previous collection provide an adequate source to create the CD34+-selected SCB. Therefore, a pilot study comparing fresh with cryopreserved stem-cell products for CD34+-selected boost infusions was conducted. This study suggested that cryopreserved products can also be an effective source for SCB because five of the eight recipients receiving SCB created from cryopreserved products achieve complete responses. Although the number of patients was relatively small, it did provide an alternative for fresh SCB. Moreover, this study showed that the addition of plerixafor can increase CD34+ yield over G-CSF alone. Recently, we also applied CD34+-selected SCB without further conditioning to treat a 26-year-old male patient of refractory secondary PGF successfully. The patient was diagnosed aplastic anemia at the age of 17 then developed treatment-related myelodysplastic syndrome, and eventually progressed to acute myeloid leukemia in need of allo-HSCT. On 11 March 2019, the patient underwent haploidentical-HSCT from his elder sister who had a 7/10 loci match with him. During the perioperative period, the patient experienced severe pulmonary infection, but, with careful anti-infection, anti-inflammatory, and supportive treatments, and the adjustment of the pre-conditioning regimen, the patient achieved neutrophil engraftment on day +15 post-HSCT. Unfortunately, he then developed severe GVHD and secondary PGF. We used MSC infusion, eltrombopag, and hematopoietic growth factors, but the efficacy was not significant. Subsequently, on 29 September, the patient received CD34+-selected SCB from his former donor and acquired hematopoietic recovery 3 weeks later (Figure 1). Given the efficacy of CD34+ SCB, Abboud et al. sought to employ CD34+ SCB infusion on day 5–6 after allo-HSCT for patients with a high risk of developing graft failure or poor graft function. They found that CD34+-selected SCB as a preventative approach can facilitate the engraftment and reduce graft failure or poor graft function with an acceptable incidence of severe acute GVHD. Although
### Table 1. Comparisons of recent clinical research in the treatment for PGF.

| Treatment | Dose | No. of patients | Response rate | Long-term survival rate | Adverse events/ incidence rate |
|-----------|------|-----------------|---------------|------------------------|-------------------------------|
| Stasia et al. | CD34\(^+\)-selected SCB | 3.4 × 10\(^6\)/kg [median] | 41 | 83% | 3-year survival: 63% | aGVHD (15%) |
| Haen et al. | CD34\(^+\)-selected SCB | 4.6 × 10\(^6\)/kg [median] | 20 | 90% in platelets 95% in leukocytes 90% in hemoglobin | 2-year survival: 53% | aGVHD (5%) |
| Ghobadi et al. | CD34\(^+\)-selected SCB | 3.1 × 10\(^6\)/kg [G-CSF only] 10.9 × 10\(^6\)/kg [G-CSF plus plerixafor] 1 × 10\(^6\)/kg [cryopreserved products] | 26 | 81% | 1-year survival: 65% | aGVHD (23%) cGVHD (31%) |
| Mainardi et al. | CD34\(^+\)-selected SCB | 3.15 × 10\(^6\)/kg [median] | 50 | 78.8% | 5-year survival: 38.67% | aGVHD (6%) |
| Cuadrado et al. | CD34\(^+\)-selected SCB | 3.2 × 10\(^6\)/kg [median] | 62 | 75.8% | 5-year survival: 54% | aGVHD (11%) cGVHD (8%) |
| Liu et al. | MSC | 1 × 10\(^6\)/kg [1–3 times] | 20 | 85% | 508 days: 45% [median follow-up time] | Infection (65%) CMV DNA viremia (10%) EBV DNA viremia (35%) EBV-associated PTLD (15%) GVHD (15%) |
| Servais et al. | MSC | 1.2 × 10\(^6\)/kg [single time] | 30 | 51.8% [day90] 69.2% [day180] | 1-year survival: 70% | No severe adverse event |
| Tang et al. | Eltrombopag | Initiated at 25 mg/day for 3 days and then increased to 50 or 75 mg/d | 12 | 83.3% | 1-year survival: 83.3% | No severe adverse event |
| Fu et al. | Eltrombopag | initiated at 25 or 50 mg/day and adjusted to a maximum of 50–100 mg/day | 15 | 60.0% | No severe adverse effect |
| Marotta et al. | Eltrombopag | initiated at 50 mg/day, and adjusted to 150 mg | 12 | 58.3% | Skin hyperpigmentation (8.3%) |
| Olivieri et al. | Deferasirox | 750 mg bid [–72 day] 625 mg/d [+89 day] and increased to 1250 mg/d | 1 | 100% | Not mentioned |

CD34\(^+\)-selected SCB indicates CD34\(^+\)-selected stem-cell boost; CMV, cytomegalovirus; EBV, Epstein–Barr virus; GVHD, graft versus host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; MSC, mesenchymal stem cell; PGF, poor graft function; PTLD, posttransplant lymphoproliferative disorders.
numerous studies suggested that the infusion of CD34+ -selected SCB is an effective way to correct poor graft function, the predictors of efficacy are unclear. A recent study \((n = 62)\) showed that in multivariate analysis, CMV seronegative status, the absence of active infection, and matched recipient/donor gender are favorable parameters that are strongly associated with the efficacy for CD34+ -selected SCB.\(^{71}\) To sum up, CD34+ -selected SCB provides an important therapeutic option with limited adverse effects for PGF following allo-SCT.

**Mesenchymal stem cells**

As indispensable components of the BM microenvironment, mesenchymal stem cells are critical in the maintenance and regulation of hematopoiesis, while MSC infusion has recently been applied to the treatment of PGF. A study by Song et al. indicated that dysfunction of BM MSCs might play a role in deficient hematopoiesis in PGF patients, and, as such, the treatment with MSCs might be an effective strategy.\(^ {54} \) MSC treatment is much more convenient than CD34+ -selected SCB and is without immunogenicity. MSCs are not required to be collected from the original donor necessarily. Instead, they can be collected from a third-party donor. A recent study \((n = 30)\) presented at the ASH (American Society of Hematology) meeting in 2019 showed good tolerance and efficacy.\(^ {73} \) The response rates at day 90 and day 180 were 51.8% (95% CI: 33.0–70.7%) and 69.2% (95% CI: 51.5–86.9%), respectively. The overall survival at 1 year after MSC treatment was 70% (95% CI: 53.6–86.3%), and no severe adverse event was reported. In a prospective study of 20 patients with PGF after allo-HSCT treated with third-party MSCs, 17 achieved hematopoietic recovery, whereas 13 developed infections, including bacterial infection, invasive fungal infection, viral infection and mixed infections.\(^ {72} \) Within the first 100 days of post-MSC treatment, five patients developed cytomegalovirus-DNA viremia, and seven developed Epstein–Barr virus (EBV)–DNA viremia. Moreover, three patients in the EBV-DNA viremia group later developed EBV-associated posttransplant lymphoproliferative disorders (PTLD). GVHD occurred in three patients, and there was no short-term toxicity. Based on these findings, we conclude that MSCs might be beneficial in the treatment of PGF patients, but whether the

![Figure 1. Dynamic changes of blood cells after CD34+ -selected SCB infusion and supportive treatments.](image-url)
New strategies
In addition to CD34+ SCB and MSCs, new drugs have also developed rapidly in recent years as new treatments. Because basic research suggested that impaired endothelial cell functions might contribute to PGF after allo-HSCT, a series of studies has been focused on the topic.\textsuperscript{53,79} Atorvastatin, a lipid-reducing drug, is used widely to treat dyslipidemia clinically. Furthermore, it reportedly improves endothelial progenitor cells (EPCs) in several diseases. Recent studies showed that atorvastatin treatment can also improve BM EPCs from patients with PGF quantitatively and functionally \textit{in vitro}.\textsuperscript{52} The \textit{in vivo} function is yet to be confirmed. In murine models, N-acetyl-L-cysteine (NAC) can facilitate the engraftment of hematopoietic stem cells by reducing the level of ROS.\textsuperscript{80} In keeping with these findings, a clinical study suggested that NAC can safely improve impaired BM EC functions in PGF patients.\textsuperscript{79} A total of 35 patients with EC < 0.1% were treated with NAC prophylactically and demonstrated the reconstitution of BM ECs and CD34+ cells with decreased incidence of PGF. Eltrombopag, a novel oral thrombopoietin (TPO) receptor agonist, can stimulate the TPO receptor (c-mpl) in both HSCs and megakaryocytes. Thus, it can promote the production of megakaryocytes and platelets and has been used in the treatment of aplastic anemia and post-transplantation thrombocytopenia. In addition, several case reports declared good efficacy of eltrombopag in treating PGF patients and shed light on subsequent clinical trials.\textsuperscript{81,82} Tang \textit{et al.} treated 12 secondary PGF patients with eltrombopag, and 10 patients (83.3%) responded to the treatment, of which 8 achieved complete response.\textsuperscript{74} The overall survival rate of 12-month was 83.3%, and no treatment-related mortality was identified. A recent single-center study (n = 12) suggested that 7 of 12 patients achieved a hematological response, and complete response could be seen in 6 patients.\textsuperscript{76} Moreover, treatment with eltrombopag was discontinued in 6/7 patients, and the response remained stable without further relapse. A study conducted in China has been focused on the treatment with eltrombopag for patients (n = 38) of refractory thrombocytopenia after haploidentical-HSCT,\textsuperscript{75} among which 15 patients were PGF. Of 15 PGF patients, 9 achieved trilineage response after eltrombopag treatment, and the duration of the response was relatively long after treatment withdrawal. Moreover, the researchers found that the presence of megakaryocytes in the BM before initia-
tion was associated with the response to eltrombopag (68.0% versus 23.1%, \( p = 0.015 \)). Five patients developed liver injury during treatment, but they all had clear causes (e.g., hepatitis E, hepatic chronic GVHD, and severe infection). Furthermore, although some patients in the study had GVHD, none of them discontinued eltrombopag, suggesting that eltrombopag can be well tolerated in patients with GVHD. All the studies showed good tolerance and no severe adverse events. Iron overload is reportedly a risk factor of PGF, and iron-cheating, therefore, may facilitate hematopoietic reconstruction. Previous studies indicated that iron chelation therapy can lead to a hematopoietic response in some patients with aplastic anemia and acute leukemia.\textsuperscript{83,84} Recently, Olivieri \textit{et al.} demonstrated that a patient diagnosed with PGF, whose underlying disease was severe aplastic anemia, achieved complete hematopoietic recovery after iron chelation treatment with deferasirox.\textsuperscript{77}

Conclusion
PGF is a serious complication with high mortality after allo-HSCT, while PGF patients have poor survival without effective treatment. Over the past decades, many studies have sought to identify risk factors pre-HSCT and suggested that low dose of infused CD34+ cells, DSA, CMV infection, GVHD, iron overload, and splenomegaly, among others, are the most important. Physicians should pay attention to risk factors before allo-HSCT, and take measures to prevent the occurrence of PGF and eventually improve survival. Although there are discrepancies in the criteria used to define PGF in previous studies, we should nonetheless be cautious about the potential risk factors, especially those overlapping among different studies. Moreover, large-scale studies with uniform diagnosis criteria are needed to verify the findings. Although the mechanism of PGF has not been well elucidated, various studies indicated that the BM microenvironment abnormalities might play a crucial role in the pathogenesis of PGF, and the treatments aimed at improving the BM microenvironment can, therefore, facilitate hematopoietic recovery. These findings have
also prompted the development of new treatment strategies. New advances in the treatment of PGF after allo-HSCT in recent years have led to three main conclusions. Firstly, CD34+ SCB (fresh or cryopreserved) without further conditioning is safe and effective in the treatment of PGF patients, and CMV seronegative status, absence of active infection and matched recipient/donor gender are favorable factors for efficacy. Secondly, mesenchymal stem cells can also improve the prognosis of PGF, but whether they can increase the risk of infections needs further studies. Finally, new strategies including NAC, eltrombopag, deferasirox, and atorvastatin, have shown good tolerance and efficacy. However, the sample size of these studies was relatively small, and some of the treatments only have produced results in the laboratory settings but not clinical settings. In the future, large-scale randomized and controlled clinical trials are needed to confirm the results. Furthermore, the potential efficacy of the therapies combining these new strategies to improve graft functions should be investigated.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by grants from the National Megaproject on Key Infectious Diseases (grant number 2017ZX10202102); the CAMS Initiative for Innovative Medicine (grant number 2016-I2M-1-017; 2016-I2M-1-018; 2019-I2M-1-006), Tianjin Municipal Natural Science Foundation (grant number 18JCZDJC44000) and the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (grant number 2018PT32034).

ORCID iD
Juan Chen https://orcid.org/0000-0002-8006-0630

References
1. Rondon G, Saliba RM, Khoury I, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. *Biol Blood Marrow Transplant* 2008; 14: 859–866.
2. Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights. *Semin Hematol* 2019; 56: 215–220.
3. Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2019; 25: 1898–1907.
4. Sun YQ, He GL, Chang YJ, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. *Ann Hematol* 2015; 94: 1699–1705.
5. Larocca A, Piaggio G, Podesta M, et al. Boost of CD34+ selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. *Haematologica* 2006; 91: 935–940.
6. Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. *Br J Haematol* 2001; 112: 219–227.
7. Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. *Bone Marrow Transplant* 2013; 48: 537–543.
8. Nakamae H, Storer B, Sandmaier BM, et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. *Haematologica* 2011; 96: 1838–1845.
9. Sun YQ, Wang Y, Zhang XH, et al. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. *Ann Hematol* 2019; 98: 1877–1883.
10. Yoshihara S, Maruya E, Taniguchi K, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. *Bone Marrow Transplant* 2012; 47: 508–515.
11. Ciurea SO, Thall PF, Wang X, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. *Blood* 2011; 118: 5957–5964.
12. Zhang R, He Y, Yang D, et al. Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation. J Clin Lab Anal 2020; e23261.

13. Chang YJ, Zhao XY, Xu LP, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 2015; 8: 84.

14. Ciurea SO, Cao K, Fernandez-Vina M, et al. The European society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific Anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2018; 53: 521–534.

15. Leffell MS, Jones RJ and Gladstone DE. Donor HLA-specific Abs: to BMT or not to BMT? Bone Marrow Transplant 2015; 50: 751–758.

16. Gladstone DE, Zachary AA, Fuchs EJ, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013; 19: 647–652.

17. Bramanti S, Calafiore V, Longhi E, et al. Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes. Biol Blood Marrow Transplant 2019; 25: 1395–1406.

18. Isidori A, Borin L, Elli E, et al. Iron toxicity - its effect on the bone marrow. Blood Rev 2018; 32: 473–479.

19. Ohmoto A, Fuji S, Miyagi-Maeshima A, et al. Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection. Bone Marrow Transplantation 2017; 52: 1201–1203.

20. Alchalby H, Yunus DR, Zabelina T, et al. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 2016; 51: 1223–1227.

21. Shimomura Y, Hara M, Katoh D, et al. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2018; 97: 1049–1056.

22. Akpek G, Pasquini MC, Logan B, et al. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 2013; 48: 825–831.

23. Cho SY, Lee DG and Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci 2019; 20: 2666.

24. Torok-Storb B, Boeckh M, Hoy C, et al. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 1997; 90: 2097–2102.

25. Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014; 209: 557–561.

26. Xiao Y, Song J, Jiang Z, et al. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci 2014; 11: 652–657.

27. Perruccio K, Sisinni L, Perez-Martinez A, et al. High incidence of early human herpesvirus-6 infection in children undergoing haploidentical manipulated stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2018; 24: 2549–2557.

28. Betts BC, Young JA, Ustun C, et al. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17: 1562–1568.

29. Chevallier P, Hebia-Fellah I, Planche L, et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010; 45: 1204–1211.

30. Winestone LE, Punn R, Tamaresis JS, et al. High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality. Pediatr Transplant 2018; 22: e13084.

31. von Bonin M and Bornhauser M. Concise review: the bone marrow niche as a target of graft versus host disease. Stem Cells 2014; 32: 1420–14281.

32. Peralvo J, Bacigalupo A, Pittaluga PA, et al. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 279–285.
33. Cluzeau T, Lambert J, Raus N, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFMG-TC and SFHI. Bone Marrow Transplant 2016; 51: 687–691.

34. Boulais PE and Frenette PS. Making sense of hematopoietic stem cell niches. Blood 2015; 125: 2621–2629.

35. Pinho S and Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol 2019; 20: 303–320.

36. Morrison SJ and Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature 2014; 505: 327–334.

37. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978; 4: 7–25.

38. Xie Y, Yin T, Wiegaebe W, et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 2009; 457: 97–101.

39. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841–846.

40. Calvi LM, Yilmaz OH, Iwashita T, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836–841.

41. Nombela-Arrieta C, Pivarnik G, Winkel B, et al. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol 2013; 15: 533–543.

42. Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109–1121.

43. Mendez-Ferrer S, Michurina TV, Ferraro P, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829–834.

44. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6: 251–264.

45. Ding L, Saunders TL, Enikolopov G, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012; 481: 457–462.

46. Ciurea SO, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009; 88: 1019–1024.

47. Parmar K, Mauch P, Vergilio JA, et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104: 5431–5436.

48. Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010; 7: 391–402.

49. Zeng L, Chen C, Song G, et al. Infusion of endothelial progenitor cells accelerates hematopoietic and immune reconstitution, and ameliorates the graft-versus-host disease after hematopoietic stem cell transplantation. Cell Biochem Biophys 2012; 64: 213–222.

50. Kong Y, Chang YJ, Wang YZ, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1465–1473.

51. Shi MM, Kong Y, Song Y, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood 2016; 128: 2988–2999.

52. Song Y, Zhao HY, Lyu ZS, et al. Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2018; 24: 1981–1989.

53. Moirangthem RD, Singh S, Adsul A, et al. Hypoxic niche-mediated regeneration of hematopoiesis in the engraftment window is dominantly affected by oxygen tension in the milieu. Stem Cells Dev 2015; 24: 2423–2436.

54. Kong Y, Song Y, Hu Y, et al. Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget 2016; 7: 30892–30906.

55. Mercier FE, Ragu C and Scadden DT. The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol 2011; 12: 49–60.
58. Zeng D, Hoffmann P, Lan F, et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 2002; 99: 1449–1457.

59. Riether C, Schurch CM and Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ 2015; 22: 187–198.

60. Zhao HY, Lyu ZS, Duan CW, et al. An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2018; 182: 679–692.

61. Wang YT, Kong Y, Song Y, et al. Increased type I immune response in the bone marrow immune microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016; 22: 1376–1382.

62. Kong Y, Wang YT, Cao XN, et al. Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. J Transl Med 2017; 15: 57.

63. Liu C, Yang Y, Wu D, et al. Inflammation-associated cytokines IGFBP1 and RANTES impair the megakaryocytic potential of HSCs in PT patients after Allo-HSCT. Biol Blood Marrow Transplant 2018; 24: 1142–1151.

64. Maruyama K, Aotsuka N, Kumano Y, et al. Immune-mediated hematopoietic failure after allogeneic hematopoietic stem cell transplantation: a common cause of late graft failure in patients with complete donor chimerism. Biol Blood Marrow Transplant 2018; 24: 43–49.

65. Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French society of bone marrow transplantation. Br J Haematol 2000; 111: 292–302.

66. Lund TC, Liegel J, Bejanyan N, et al. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol 2015; 90: 892–896.

67. Stasia A, Ghiso A, Galaverna F, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1440–1443.

68. Haen SP, Schumm M, Paul C, et al. Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation. J Cancer Res Clin Oncol 2015; 141: 2241–2251.

69. Ghobadi A, Fiala MA, Ramsingh G, et al. Fresh or Cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2017; 23: 1072–1080.

70. Mainardi C, Ebinger M, Enkel S, et al. CD34+-selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol 2018; 180: 90–99.

71. Cuadrado MM, Szydlo RM, Watts M, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. Epub ahead of print 21 November 2019. DOI: 10.3324/haematol.2019.226340.

72. Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2014; 23: 1087–1098.

73. Servais S, Baron F, Lechanteur C, et al. Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation: a multicenter prospective study. Blood 2019; 134: 37.

74. Tang C, Chen F, Kong D, et al. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J Hematol Oncol 2018; 11: 103.

75. Fu H, Zhang X, Han T, et al. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 2019; 54: 1310–1318.

76. Marotta S, Marano L, Ricci P, et al. Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant 2019; 54: 1346–1353.

77. Olivieri J, Mancini G, Goteri G, et al. Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia. Leuk Lymphoma 2016; 57: 965–968.

78. Abboud R, Slade M, Abboud C, et al. Can planned CD34+ stem cell boost prevent...
poor graft function after peripheral blood haploidentical hematopoietic transplantation? Biol Blood Marrow Transplant 2020; 26: S296.

79. Kong Y, Wang Y, Zhang YY, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv 2019; 3: 1303–1317.

80. Hu L, Cheng H, Gao Y, et al. Antioxidant N-acetyl-L-cysteine increases engraftment of human hematopoietic stem cells in immune-deficient mice. Blood 2014; 124: e45–e48.

81. Dyba J, Tinmouth A, Bredeson C, et al. Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature. Transf Med 2016; 26: 202–207.

82. Master S, Dware A, Mansour R, et al. Use of eltrombopag in improving poor graft function after allogeneic hematopoietic stem cell transplantation. Case Rep Oncol 2018; 11: 191–195.

83. Lee JW, Yoon SS, Shen ZX, et al. Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica 2013; 98: 1045–1048.

84. Visani G, Guiducci B, Giardini C, et al. Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49: 585–587.